NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?
Recent share performance and business context
Rhythm Pharmaceuticals (RYTM) has drawn investor attention after a recent period in which the stock fell 7% over the past month but gained about 21% over the past 3 months.
The company focuses on treatments for rare neuroendocrine diseases, with commercial revenue of about US$217.2 million and a reported net loss of roughly US$207.8 million, which keeps profitability in clear focus for shareholders.
See our latest analysis for Rhythm...